C3 Glomerulopathy: Ten Years’ Experience at Mayo Clinic

Aishwarya Ravindran, Fernando Custodio Fervenza, Richard J.H. Smith, An S. De Vriese, Sanjeev M Sethi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: To describe the clinicopathological features, complement abnormalities, triggers, treatment, and outcomes of C3 glomerulopathy. Patients and Methods: A total of 114 patients with C3 glomerulopathy seen at Mayo Clinic from January 1, 2007, through December 31, 2016, were evaluated in this study. Results: The mean age at diagnosis for the entire cohort was 40.4±22.3 years, with a median serum creatinine level and proteinuria value of 1.6 mg/dL (range: 0.3-14.7) (to convert to mmol/L, multiply by 0.0259) and 2605 mg/24 h (range: 233-24,165), respectively. Hematuria was present in 100 patients (87.7%). The C3 and C4 levels were low in 50 of 112 (44.6%) and 13 of 110 (11.8%) patients, respectively. A history of infection, positive autoimmune findings, and monoclonal gammopathy (MIg) were present in 33 of 114 (28.9%), 28 of 114 (24.6%), and 36 of 95 (37.9%) patients, respectively. However, 28 of 43 patients 50 years or older (65.1%) had MIg. A genetic variant in complement genes, C3 nephritic factor (C3Nef), and other autoantibodies was present in 26 of 70 (37.1%), 30 of 69 (43.5%), and 9 of 67 (13.4%) patients, respectively. Membranoproliferative and mesangial proliferative glomerulonephritis were the common patterns of injury. Patients without MIg were younger (mean age, 32.3±20.6 years), with a median serum creatinine level and proteinuria value of 1.4 mg/dL (range: 0.3-7.9) and 2450 mg/24 h (range: 250-24, 165) and with low C3 and C4 levels in 38 of 77 (49.4%) and 9 of 75 (12.0%) patients, respectively. Most patients received corticosteroids and other immunosuppressive drugs. In patients without MIg, at a median follow-up of 22.3 months (range: 0.1-201.1), the median serum creatinine level and proteinuria value were 1.4 mg/dL (range: 0.3-3.7) and 825.5 mg/24 h (range: 76-22, 603), and 7 patients (9.2%) had progression to end-stage renal disease. Conclusion: C3 glomerulopathy is a heterogeneous disease entity with complex triggering events and abnormalities of the alternative pathway of complement. The disease tends to be progressive and exhibits a variable response to immunosuppressive therapy.

Original languageEnglish (US)
Pages (from-to)991-1008
Number of pages18
JournalMayo Clinic Proceedings
Volume93
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Proteinuria
Creatinine
Immunosuppressive Agents
Complement C3 Nephritic Factor
Serum
Alternative Complement Pathway
Paraproteinemias
Hematuria
Glomerulonephritis
Autoantibodies
Chronic Kidney Failure
Adrenal Cortex Hormones
Wounds and Injuries
Infection
Pharmaceutical Preparations
Genes
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

C3 Glomerulopathy : Ten Years’ Experience at Mayo Clinic. / Ravindran, Aishwarya; Fervenza, Fernando Custodio; Smith, Richard J.H.; De Vriese, An S.; Sethi, Sanjeev M.

In: Mayo Clinic Proceedings, Vol. 93, No. 8, 01.08.2018, p. 991-1008.

Research output: Contribution to journalArticle

Ravindran, Aishwarya ; Fervenza, Fernando Custodio ; Smith, Richard J.H. ; De Vriese, An S. ; Sethi, Sanjeev M. / C3 Glomerulopathy : Ten Years’ Experience at Mayo Clinic. In: Mayo Clinic Proceedings. 2018 ; Vol. 93, No. 8. pp. 991-1008.
@article{b68bd08db3354fd0825355b1c51659a5,
title = "C3 Glomerulopathy: Ten Years’ Experience at Mayo Clinic",
abstract = "Objective: To describe the clinicopathological features, complement abnormalities, triggers, treatment, and outcomes of C3 glomerulopathy. Patients and Methods: A total of 114 patients with C3 glomerulopathy seen at Mayo Clinic from January 1, 2007, through December 31, 2016, were evaluated in this study. Results: The mean age at diagnosis for the entire cohort was 40.4±22.3 years, with a median serum creatinine level and proteinuria value of 1.6 mg/dL (range: 0.3-14.7) (to convert to mmol/L, multiply by 0.0259) and 2605 mg/24 h (range: 233-24,165), respectively. Hematuria was present in 100 patients (87.7{\%}). The C3 and C4 levels were low in 50 of 112 (44.6{\%}) and 13 of 110 (11.8{\%}) patients, respectively. A history of infection, positive autoimmune findings, and monoclonal gammopathy (MIg) were present in 33 of 114 (28.9{\%}), 28 of 114 (24.6{\%}), and 36 of 95 (37.9{\%}) patients, respectively. However, 28 of 43 patients 50 years or older (65.1{\%}) had MIg. A genetic variant in complement genes, C3 nephritic factor (C3Nef), and other autoantibodies was present in 26 of 70 (37.1{\%}), 30 of 69 (43.5{\%}), and 9 of 67 (13.4{\%}) patients, respectively. Membranoproliferative and mesangial proliferative glomerulonephritis were the common patterns of injury. Patients without MIg were younger (mean age, 32.3±20.6 years), with a median serum creatinine level and proteinuria value of 1.4 mg/dL (range: 0.3-7.9) and 2450 mg/24 h (range: 250-24, 165) and with low C3 and C4 levels in 38 of 77 (49.4{\%}) and 9 of 75 (12.0{\%}) patients, respectively. Most patients received corticosteroids and other immunosuppressive drugs. In patients without MIg, at a median follow-up of 22.3 months (range: 0.1-201.1), the median serum creatinine level and proteinuria value were 1.4 mg/dL (range: 0.3-3.7) and 825.5 mg/24 h (range: 76-22, 603), and 7 patients (9.2{\%}) had progression to end-stage renal disease. Conclusion: C3 glomerulopathy is a heterogeneous disease entity with complex triggering events and abnormalities of the alternative pathway of complement. The disease tends to be progressive and exhibits a variable response to immunosuppressive therapy.",
author = "Aishwarya Ravindran and Fervenza, {Fernando Custodio} and Smith, {Richard J.H.} and {De Vriese}, {An S.} and Sethi, {Sanjeev M}",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.mayocp.2018.05.019",
language = "English (US)",
volume = "93",
pages = "991--1008",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - C3 Glomerulopathy

T2 - Ten Years’ Experience at Mayo Clinic

AU - Ravindran, Aishwarya

AU - Fervenza, Fernando Custodio

AU - Smith, Richard J.H.

AU - De Vriese, An S.

AU - Sethi, Sanjeev M

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Objective: To describe the clinicopathological features, complement abnormalities, triggers, treatment, and outcomes of C3 glomerulopathy. Patients and Methods: A total of 114 patients with C3 glomerulopathy seen at Mayo Clinic from January 1, 2007, through December 31, 2016, were evaluated in this study. Results: The mean age at diagnosis for the entire cohort was 40.4±22.3 years, with a median serum creatinine level and proteinuria value of 1.6 mg/dL (range: 0.3-14.7) (to convert to mmol/L, multiply by 0.0259) and 2605 mg/24 h (range: 233-24,165), respectively. Hematuria was present in 100 patients (87.7%). The C3 and C4 levels were low in 50 of 112 (44.6%) and 13 of 110 (11.8%) patients, respectively. A history of infection, positive autoimmune findings, and monoclonal gammopathy (MIg) were present in 33 of 114 (28.9%), 28 of 114 (24.6%), and 36 of 95 (37.9%) patients, respectively. However, 28 of 43 patients 50 years or older (65.1%) had MIg. A genetic variant in complement genes, C3 nephritic factor (C3Nef), and other autoantibodies was present in 26 of 70 (37.1%), 30 of 69 (43.5%), and 9 of 67 (13.4%) patients, respectively. Membranoproliferative and mesangial proliferative glomerulonephritis were the common patterns of injury. Patients without MIg were younger (mean age, 32.3±20.6 years), with a median serum creatinine level and proteinuria value of 1.4 mg/dL (range: 0.3-7.9) and 2450 mg/24 h (range: 250-24, 165) and with low C3 and C4 levels in 38 of 77 (49.4%) and 9 of 75 (12.0%) patients, respectively. Most patients received corticosteroids and other immunosuppressive drugs. In patients without MIg, at a median follow-up of 22.3 months (range: 0.1-201.1), the median serum creatinine level and proteinuria value were 1.4 mg/dL (range: 0.3-3.7) and 825.5 mg/24 h (range: 76-22, 603), and 7 patients (9.2%) had progression to end-stage renal disease. Conclusion: C3 glomerulopathy is a heterogeneous disease entity with complex triggering events and abnormalities of the alternative pathway of complement. The disease tends to be progressive and exhibits a variable response to immunosuppressive therapy.

AB - Objective: To describe the clinicopathological features, complement abnormalities, triggers, treatment, and outcomes of C3 glomerulopathy. Patients and Methods: A total of 114 patients with C3 glomerulopathy seen at Mayo Clinic from January 1, 2007, through December 31, 2016, were evaluated in this study. Results: The mean age at diagnosis for the entire cohort was 40.4±22.3 years, with a median serum creatinine level and proteinuria value of 1.6 mg/dL (range: 0.3-14.7) (to convert to mmol/L, multiply by 0.0259) and 2605 mg/24 h (range: 233-24,165), respectively. Hematuria was present in 100 patients (87.7%). The C3 and C4 levels were low in 50 of 112 (44.6%) and 13 of 110 (11.8%) patients, respectively. A history of infection, positive autoimmune findings, and monoclonal gammopathy (MIg) were present in 33 of 114 (28.9%), 28 of 114 (24.6%), and 36 of 95 (37.9%) patients, respectively. However, 28 of 43 patients 50 years or older (65.1%) had MIg. A genetic variant in complement genes, C3 nephritic factor (C3Nef), and other autoantibodies was present in 26 of 70 (37.1%), 30 of 69 (43.5%), and 9 of 67 (13.4%) patients, respectively. Membranoproliferative and mesangial proliferative glomerulonephritis were the common patterns of injury. Patients without MIg were younger (mean age, 32.3±20.6 years), with a median serum creatinine level and proteinuria value of 1.4 mg/dL (range: 0.3-7.9) and 2450 mg/24 h (range: 250-24, 165) and with low C3 and C4 levels in 38 of 77 (49.4%) and 9 of 75 (12.0%) patients, respectively. Most patients received corticosteroids and other immunosuppressive drugs. In patients without MIg, at a median follow-up of 22.3 months (range: 0.1-201.1), the median serum creatinine level and proteinuria value were 1.4 mg/dL (range: 0.3-3.7) and 825.5 mg/24 h (range: 76-22, 603), and 7 patients (9.2%) had progression to end-stage renal disease. Conclusion: C3 glomerulopathy is a heterogeneous disease entity with complex triggering events and abnormalities of the alternative pathway of complement. The disease tends to be progressive and exhibits a variable response to immunosuppressive therapy.

UR - http://www.scopus.com/inward/record.url?scp=85050333890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050333890&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.05.019

DO - 10.1016/j.mayocp.2018.05.019

M3 - Article

C2 - 30077216

AN - SCOPUS:85050333890

VL - 93

SP - 991

EP - 1008

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -